Agios: Mitapivat’s Indication Stack Is Turning Into a Commercial Flywheel — A Long Trade with Defined Risk
Mitapivat's expanding label set — recent FDA priority review for sickle cell plus durable hemoglobin and transfusion benefits — gives Agios ($AGIO) a chance to convert clinical momentum into accelerating sales. The balance sheet and recent revenue cadence reduce binary regulatory exposure, but valuation and competition keep risk elevated. Trade pla…